FGP
PCRX icon

Freestone Grove Partners’s Pacira BioSciences PCRX Stock Holding History

Freestone Grove Partners’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$127 Sell
5
-36,417
-100% -$861K ﹤0.01% 921
2026
Q1 		$823K Sell
36,422
-410
-1% -$9.11K 0.01% 510
2025
Q4 		$953K Buy
+36,832
New +$876K 0.01% 472

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Freestone Grove Partners's PCRX Position: Q2 2026 in Review

Freestone Grove Partners reduced its Pacira BioSciences (PCRX) stake by 100% in Q2 2026, selling an estimated $861K and leaving 5 shares worth $127. The position accounts for ﹤0.01% of the portfolio, ranked #921.

Freestone Grove Partners first reported a position in PCRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $953K in Q4 2025. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Freestone Grove Partners held 5 shares of Pacira BioSciences worth $127 as of Q2 2026.
  • Freestone Grove Partners sold 36,417 Pacira BioSciences shares in Q2 2026, an estimated $861K.
  • Pacira BioSciences made up ﹤0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #921 holding.
  • Freestone Grove Partners first reported a position in Pacira BioSciences in Q4 2025 and has held it in 3 quarters since.
  • Freestone Grove Partners's Pacira BioSciences position peaked at $953K in Q4 2025.
  • 253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.